Compare Cassava Sciences Inc (FLNA) vs Infosys Limited (INFY) Price & Performance

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

INFY trades at $11.46, up 3.71% today, with a bearish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.23 beating expectations. Fundamentals show robust profitability with a net income margin of 16.44% and ROE of 31.57%, while valuation ratios like P/E of 13.8 and EV/EBITDA of 8.5 suggest reasonable pricing. Recent news highlights Infosys' expanding AI collaborations across healthcare, banking, and media sectors.

The outlook is mixed; analyst consensus is a 'Hold' with a $12.14 price target, implying modest upside. Strengths include solid cash flow and AI-driven growth initiatives, but risks involve competitive pressures in IT services and potential volatility from global tech spending trends. The stock presents a value opportunity with steady dividends, though investor sentiment remains cautious amid sector headwinds.